Dietary Curcuma, a Powerful Epigenome Modulator in Breast Cancer: an In Silico Study
Abstract
The inhibition of DNA methyltransferase-1 enzyme can strongly decrease the capacity of cells to enhance the tumour-genesis process. Members of the Estrogen-Related Receptors family regulate several elements of cellular metabolism. These are orphan nuclear receptors that regulate a wide range of functional gene networks involved in breast carcinogenesis and the regulation of associated methionine and folate cycles, providing a proven direct relationship to DNA methylation as a result. Moreover, dietary phytochemicals, such as Curcumin, can involve epigenetic modification, which may decrease the development of many types of cancer, especially breast cancer in women. We conducted this study to investigate the effect of Curcuma (PubChem ID: 969516) on the epigenetic modification and inhibition of the DNA methyltransferase-1 (PDB ID: 3PTA) activity and Estrogen-Related Receptors (PDB ID: 1XB7) using Molecular docking approach and computational tools that may inform whether the Curcuma could provide this protective anticancer effect or not. Interestingly, the DNA methyltrasferase1-Curcumin and Estrogen-Related Receptors-Curcumin complexes display a docking score of -6.9 and -7.1 kcal/mol, respectively. Furthermore, Curcumin displays hydrogen, Pi-Cation, Pi-Anion and Van der Waals bonds with active site residues of the targeted molecules. By targeting DNA methylation via the combined inhibition of estrogen-related receptors and DNMT1, our research opens up a new therapeutic path for breast cancer treatment.
Keywords: curcumin, breast cancer, epigenetic, molecular docking, treatment.
Full Text:
PDFReferences
Al-Kharashi, L.A., Al-Mohanna, F.H., Tulbah, A., and Aboussekhra, A., 2018, The DNA methyl-transferase protein DNMT1 enhances tumor-promoting properties of breast stromal fibroblasts, Oncotarget, 9(2), 2329–2343. CrossRef
Anstine, L.J., and Keri, R., 2019, A new view of the mammary epithelial hierarchy and its implications for breast cancer initiation and metastasis, J Cancer Metastasis Treat., 5, 50. CrossRef
Audet-Walsh, É., Papadopoli, D.J., Gravel, S.-P., Yee, T., Bridon, G., Caron, M., et al., 2016, The PGC-1α/ERRα Axis Represses One-Carbon Metabolism and Promotes Sensitivity to Anti-folate Therapy in Breast Cancer, Cell Reports, 14(4), 920–931. CrossRef
Baylin, S.B., and Jones, P.A., 2016, Epigenetic Determinants of Cancer, Cold Spring Harb Perspect Biol., 8(9), a019505. CrossRef
Bickerton, G.R., Paolini, G.V., Besnard, J., Muresan, S., and Hopkins, A.L., 2012, Quantifying the chemical beauty of drugs, Nature Chem., 4(2), 90–98. CrossRef
Cai, Q., Lin, T., Kamarajugadda, S., and Lu, J., 2013, Regulation of glycolysis and the Warburg effect by estrogen-related receptors, Oncogene, 32(16), 2079–2086. CrossRef
Chatterjee, B., Ghosh, K., and Kanade, S.R., 2019, Curcumin‐mediated demethylation of the proximal promoter CpG island enhances the KLF4 recruitment that leads to increased expression of p21Cip1 in vitro, J Cell Biochem, 120(1), 809–820. CrossRef
Cheng, J.C., Matsen, C.B., Gonzales, F.A., Ye, W., Greer, S., Marquez, V.E., et al., 2003, Inhibition of DNA Methylation and Reactivation of Silenced Genes by Zebularine, JNCI Journal of the National Cancer Institute, 95(5), 399–409. CrossRef
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., et al., 2019, Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials, Signal Transduct Target Ther, 4, 62. CrossRef
Deblois, G., and Giguère, V., 2013, Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond, Nat Rev Cancer, 13(1), 27–36. CrossRef
Dong, J., Wang, N.-N., Yao, Z.-J., Zhang, L., Cheng, Y., Ouyang, D., et al., 2018, ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database, J Cheminform, 10(1), 29. CrossRef
Duijf, P.H.G., Nanayakkara, D., Nones, K., Srihari, S., Kalimutho, M., and Khanna, K.K., 2019, Mechanisms of Genomic Instability in Breast Cancer, Trends in Molecular Medicine, 25(7), 595–611. CrossRef
Elbasyouni, A., Saadi, L., and Baha, A., 2021, Epidemiological profile and distribution of prognostic factors in invasive breast cancer among Algerian women, OncoReview, 10(4), 95-101. CrossRef
Ertl, P., and Schuffenhauer, A., 2009, Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions, Journal of Cheminformatics, 1, 8. CrossRef
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., et al., 2018, Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis, Genes & Diseases, 5(2), 77–106. CrossRef
Giguère, V., 2008, Transcriptional Control of Energy Homeostasis by the Estrogen-Related Receptors, Endocrine Reviews, 29(6), 677–696. CrossRef
Gnyszka, A., Jastrzębski, Z., and Flis, S., 2013, DNA Methyltransferase Inhibitors and Their Emerging Role in Epigenetic Therapy of Cancer, Anticancer Research, 33(8), 2989-2996. CrossRef
Gupta, T., Singh, J., Kaur, S., Sandhu, S., Singh, G., and Kaur, I.P., 2020, Enhancing Bioavailability and Stability of Curcumin Using Solid Lipid Nanoparticles (CLEN): A Covenant for Its Effectiveness, Front. Bioeng. Biotechnol., 8, 879. CrossRef
Hassan, F., Rehman, M.S., Khan, M.S., Ali, M.A., Javed, A., Nawaz, A., and Yang, C., 2019, Curcumin as an Alternative Epigenetic Modulator: Mechanism of Action and Potential Effects, Front. Genet, 10, 514. CrossRef
Hassan, H.E., Keita, J.-A., Narayan, L., Brady, S.M., Frederick, R., Carlson, S., et al., 2016, The combination of dimethoxycurcumin with DNA methylation inhibitor enhances gene re-expression of promoter-methylated genes and antagonizes their cytotoxic effect, Epigenetics, 11, 740–749. CrossRef
Jones, P.A., n.d. Targeting the cancer epigenome for therapy 12.
Khor, T.O., Huang, Y., Wu, T.-Y., Shu, L., Lee, J., and Kong, A.-N.T., 2011, Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation, Biochemical Pharmacology, 82, 1073–1078. CrossRef
Kurita, T., and Makino, Y., 2013, Novel Curcumin Oral Delivery Systems, Anticancer Research, 15.
Lei, J.T., Anurag, M., Haricharan, S., Gou, X., and Ellis, M.J., 2019, Endocrine therapy resistance: new insights, The Breast, 48, S26–S30. CrossRef
Liu, Z., Xie, Z., Jones, W., Pavlovicz, R.E., Liu, S., Yu, J., et al., 2009, Curcumin is a potent DNA hypomethylation agent, Bioorganic & Medicinal Chemistry Letters, 19, 706–709. CrossRef
Lyko, F., 2018, The DNA methyltransferase family: a versatile toolkit for epigenetic regulation, Nat Rev Genet, 19, 81–92. CrossRef
Madhavi, D., and Kagan, D., 2014, Bioavailability of a Sustained Release Formulation of Curcumin, Integrative Medicine, 13, 7.
Mirza, S., Sharma, G., Parshad, R., Gupta, S.D., Pandya, P., and Ralhan, R., 2013, Expression of DNA Methyltransferases in Breast Cancer Patients and to Analyze the Effect of Natural Compounds on DNA Methyltransferases and Associated Proteins, J Breast Cancer, 16, 23. CrossRef
Momenimovahed, Z., and Salehiniya, H., 2019, Epidemiological characteristics of and risk factors for breast cancer in the world, BCTT, 11, 151–164. CrossRef
Rahimi, H.R., Nedaeinia, R., Shamloo, A.S., Nikdoust, S., and Oskuee, R.K., 2016, Novel delivery system for natural products: Nano-curcumin formulations, Aviecenna J Phytomed, 6(4), 383-398.
Russo, G.L., Vastolo, V., Ciccarelli, M., Albano, L., Macchia, P.E., and Ungaro, P., 2017, Dietary polyphenols and chromatin remodeling, Critical Reviews in Food Science and Nutrition, 57, 2589–2599. CrossRef
Schiborr, C., Kocher, A., Behnam, D., Jandasek, J., Toelstede, S., and Frank, J., 2014, The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes, Mol. Nutr. Food Res., 58, 516–527. CrossRef
Sheaffer, K.L., Elliott, E.N., and Kaestner, K.H., 2016, DNA Hypomethylation Contributes to Genomic Instability and Intestinal Cancer Initiation, Cancer Prev Res, 9, 534–546. CrossRef
Shu, L., Khor, T.O., Lee, J.-H., Boyanapalli, S.S.S., Huang, Y., Wu, T.-Y., et al., 2011, Epigenetic CpG Demethylation of the Promoter and Reactivation of the Expression of Neurog1 by Curcumin in Prostate LNCaP Cells, AAPS J, 13, 606–614. CrossRef
Stohs, S.J., Chen, O., Ray, S.D., Ji, J., Bucci, L.R., and Preuss, H.G., 2020, Highly Bioavailable Forms of Curcumin and Promising Avenues for Curcumin-Based Research and Application: A Review, Molecules, 25, 1397. CrossRef
Stresemann, C., and Lyko, F., 2008, Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine, Int. J. Cancer, 123, 8–13. CrossRef
Vernier, M., McGuirk, S., Dufour, C.R., Wan, L., Audet-Walsh, E., St-Pierre, J., and Giguère, V., 2020, Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4, Oncogene, 39(41), 6406–6420. CrossRef
Yallapu, M.M., Nagesh, P.K.B., Jaggi, M., and Chauhan, S.C., 2015, Therapeutic Applications of Curcumin Nanoformulations, AAPS J, 17(6), 1341–1356. CrossRef
Yavarpour-Bali, H., Ghasemi-Kasman, M., and Pirzadeh, M., 2019, Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders, Int J Nanomedicine, 14, 4449–4460. CrossRef
Yu, Z., Xiao, Q., Zhao, L., Ren, J., Bai, X., Sun, M., et al., 2015, DNA methyltransferase 1/3a overexpression in sporadic breast cancer is associated with reduced expression of estrogen receptor-alpha/breast cancer susceptibility gene 1 and poor prognosis: Corelation of DNMT1/3A with Prognosis in Breast Cancer, Mol. Carcinog., 54, 707–719. CrossRef
Zhang, J., Hu, Z., Lu, C., Bai, K., Zhang, L., and Wang, T., 2015, Effect of Various Levels of Dietary Curcumin on Meat Quality and Antioxidant Profile of Breast Muscle in Broilers, J. Agric. Food Chem., 63, 3880–3886. CrossRef
DOI: http://dx.doi.org/10.14499/indonesianjcanchemoprev13iss1pp61-70
Copyright (c) 2022 Indonesian Journal of Cancer Chemoprevention
Indexed by:
Indonesian Society for Cancer Chemoprevention
